Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Leukemia and Lymphoma

Volumn 56, Issue 9, 2015, Pages 2543-2551

  Hexner, Elizabeth O ^a   Mascarenhas, John ^b   Prchal, Josef ^c   Roboz, Gail J ^d   Baer, Maria R ^e   Ritchie, Ellen K ^d   Leibowitz, David ^f   Demakos, Erin P ^b   Miller, Crystal ^b   Siuty, James ^b   Kleczko, Jill ^b   Price, Leah ^g   Jeschke, Grace ^a   Weinberg, Rona ^h   Basu, Titiksha ⁱ   Pahl, Heike L ⁱ   Orazi, Attilio ^d   Najfeld, Vesna ^b   Marchioli, Roberto ^j   Goldberg, Judith D ^g   Silverman, Lewis R ^b   Hoffman, Ronald ^b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f PALO ALTO MEDICAL FOUNDATION   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h NEW YORK BLOOD CENTER   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j IQVIA   (United States)

more..

Author keywords

JAK2V617F; Lestuartinib; myelofibrosis; pharmacodynamics; pharmacokinetics; phase I trial

Indexed keywords

HYDROXYUREA; JANUS KINASE 2; LESTAURTINIB; STAT5 PROTEIN; CARBAZOLE DERIVATIVE; JAK2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; ANEMIA; ANOREXIA; ARTICLE; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; EDEMA; ENZYME INHIBITION; FEMALE; FEVER; FLATULENCE; GASTRITIS; GASTROINTESTINAL TOXICITY; HEMORRHOID; HUMAN; HYPERBILIRUBINEMIA; IN VIVO STUDY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MUSCLE WEAKNESS; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PANCREATITIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENETICS; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; JANUS KINASE 2; LEUKOPENIA; MALE; MIDDLE AGED; MUTATION, MISSENSE; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946040970     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.1001986     Document Type: Article

References (22)

1. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005; 352: 1744-1746.
2. Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-887.
3. Levis M, Allebach J, Tse KF, et al. A FLT3-Dargeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
4. Smith BD, Levis M, Beran M, et al. Single-Agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-3676.
5. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108: 3262-3270.
6. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.
7. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701)is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111: 5663-5671.
8. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.
9. Hexner E, Roboz G, Hoffman R, et al. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Br J Haematol 2014; 164: 83-93.
10. Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106: 2849-2853.
11. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
12. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
13. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
14. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82-88.
15. Jones WF Jr, Finland M. Blood levels from orally administered penicillins G and V; relation to food intake. N Engl J Med 1955; 253: 754-761.
16. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108: 3477-3483.
17. Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 2013; 4: 15-35.
18. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118: 401-408.
19. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
20. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
21. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 521-528.
22. Kalota A, Jeschke GR, Carroll M, et al. Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013; 19:1729-1739.